Ovagen Dosage, half-life & reference guide
Also known as Glu-Asp-Leu · EDL peptide
Reviewed Evidence: EmergingPublished by PepVault
A three-amino-acid peptide from the Russian bioregulator program, which its developers list for the liver and kidneys. In rats with acute kidney injury from drugs or a cut-off blood supply, it protected kidney function better than related peptides. No human study has been published.
- How often
- Daily
- Half-life
- Unknown
- Evidence
- ●
●●Emerging - Routes
- SubQ, Oral capsules
No human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference.
How it works.
A tripeptide, Glu-Asp-Leu (EDL), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers list for the liver and the kidneys. In rats with acute kidney injury, from the cancer drug cisplatin, the antibiotic gentamicin or a cut-off blood supply, EDL kept urine flowing, lowered protein and waste in the blood and urine and protected the kidneys' antioxidant enzymes, more strongly than the other peptides tested beside it. In the lab it binds DNA at particular sequences. No human study of Ovagen is indexed on PubMed, and its papers name it only by its sequence.
Commonly reported: Little to feel; user reports are few.

Where Ovagen works.

Gut
In animals. In rats with acute kidney injury from drugs or a cut-off blood supply, it protected kidney function better than related peptides.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Not established (no human data)
- Peak effect
- Not established
- Duration
- Courses of 20–30 days (community practice)
Day 1–14Community
A quiet course
Ovagen has no human studies, and users who share their runs mostly report little to feel. Commonly reported: mild discomfort where it goes in.
Updated Nov 2026
Day 14–60Animal
What the rat kidney studies found
In rats with acute kidney injury from drugs or a cut-off blood supply, EDL, the peptide in Ovagen, protected kidney function better than the related peptides tested beside it. If you have kidney blood work planned, it is the measure those studies used.
The science
Zamorskii 2015: in rats with cisplatin acute renal failure, the kidney polypeptide complex and EDL and AEDG normalized diuresis, urine creatinine, glomerular filtration and sodium reabsorption and lowered urine protein; EDL was the most potent. Zamorskii 2017: in gentamicin nephropathy and ischemia-reperfusion injury, EDL prevented oliguria and azotemia, lowered proteinuria and sodium loss, kept antioxidant enzymes up and normalized kidney energy supply.
Sources- Zamorskii et al. (2015)
- Zamorskii et al. (2017)
Updated Nov 2026
Any dayAnimal
What Ovagen is built on
A three-amino-acid peptide from the Russian bioregulator program, listed by its developers for the liver and kidneys. Its evidence is two rat studies of acute kidney injury and computer models of how it binds DNA; there is no human study.
The science
Khavinson 2021 review (Table 5): "EDL, Ovagen — regulation of renal cells' function, hepatoprotection, DNA binding". Zamorskii 2015 and 2017: rat kidney injury models. Khavinson 2016: in docking models, AEDL and EDL bind the ctcc sequence.
Sources- Khavinson et al. (2021)
- Zamorskii et al. (2015)
- Zamorskii et al. (2017)
- Khavinson et al. (2016)
Updated Nov 2026
With EpitalonCommunity
Beside the pineal peptide
Ovagen is commonly run beside other bioregulators, the pineal one among them. In the cisplatin kidney study, Epitalon's sequence (AEDG) also protected rat kidneys, less than EDL did. No study has given the two together.
The science
Zamorskii 2015: the kidney complex, EDL and AEDG normalized kidney measures in cisplatin-injured rats, EDL most potently. The pairing in stacks is community practice.
Sources- Zamorskii et al. (2015)
Updated Nov 2026
Day 1 is the day you start it.
No human study of Ovagen has been published. The effects come from two rat studies of acute kidney injury and from its developers' DNA models.
Preliminary research
A typical run.
Run notes
- Cycle
- Run in courses rather than continuously, like the other bioregulators: community capsule courses run 20–30 days, repeated every few months. No study in people has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- No timing has been studied.
- Routes
- SubQ injection, Oral capsules
- Stacks
- Epitalon
Safety.
Common side effects
- Injection-site discomfort
Interactions
No interaction studies exist, including with medicines that are hard on the kidneys or liver.
Safety notes
No safety study exists: no human study of Ovagen is indexed, so nothing is known about its side effects beyond user reports, or about long-term use. Discuss with your clinician before use, particularly during pregnancy or breastfeeding, or with a liver or kidney condition, which needs its own care.
Goes with.
One question at a time.
Compared with.
Questions people ask.
What is Ovagen?
A three-amino-acid peptide from the Russian bioregulator program, which its developers list for the liver and kidneys. In rats with acute kidney injury from drugs or a cut-off blood supply, it protected kidney function better than related peptides. No human study has been published.
How is Ovagen dosed in research?
The library carries no reference dose for Ovagen. No human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference.
How long does Ovagen last?
The half-life of Ovagen is unknown (never measured).
What do people report on Ovagen?
Commonly reported on Ovagen: little to feel; user reports are few.
Is Ovagen safe?
The research basis for Ovagen is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site discomfort.
What does Ovagen stack with?
Common stacks for Ovagen: Epitalon.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown
Unknown (never measured)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
Reviewed How we check the library
